PPARGC1A and obesity due to melanocortin 4 receptor deficiency: In humans, PPARGC1A has been thoroughly investigated because of its presumed role in the obesity pandemic and correlated diseases like type II diabetes mellitus and cardiovascular complications, especially in search of possible future therapies [19-21].